Pulmonary atresia is a heart defect present at birth (congenital) that's normally diagnosed within the first few hours or days of life. In pulmonary atresia, the valve that lets blood out of the heart to go to your baby's lungs doesn't form correctly. Instead of opening and closing to allow blood to travel from your heart to your lungs, a solid sheet of tissue forms. Blood from the right side of your baby's heart can't go back to the lungs to pick up oxygen.Pulmonary atresia may occur with or without a ventricular septal defect (VSD).
Bluish colored skin (cyanosis), Fast breathing, Fatigue, Poor eating habits (babies may get tired while nursing or sweat during feedings), Shortness of breath.Generally treatment of pulmonary atresia depends on the child’s health, age, and medical history, and in what way the condition is affecting the child. But usually, surgery will be required to treat the heart defect and helps to improve blood flow to the lungs. The temporary measure, which has to be taken in new-borns with pulmonary atresia, is usually given an intravenous drug (injected into a vein) called prostaglandin E1 to prevent the ductus arteriosus from closing
Disease statistical analysis in Russia on pulmonary atresia gave the result as thirty-seven patients were reported to have pathogenic/likely pathogenic results, while 40 had findings of unknown significance. This gives a detection rate of 11% for clinically significant (pathogenic/likely pathogenic) findings. The significant findings have prompted clinical actions in 28 out of 37 patients (75.7%), while the findings with unknown significance have led to further management recommendation in only 1 patient (p<0.001).